Valuation: FamiCord AG

Market Cap 49.85M 56.69M 46.31M 42.6M 79.88M 5.49B 81.32M 554M 216M 2.68B 213M 208M 9.29B P/E 2026 *
286x
P/E 2027 * 47.7x
Enterprise Value 57.85M 65.78M 53.75M 49.43M 92.7M 6.37B 94.36M 643M 251M 3.11B 247M 242M 10.78B EV / Sales 2026 *
0.68x
EV / Sales 2027 * 0.63x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 day-46.82%
Current month-46.82%
1 month-46.82%
3 months-46.82%
6 months-46.82%
Current year-46.82%
1 month 3.39
Extreme 3.39
3.39
Current year 3.39
Extreme 3.39
3.39
1 year 3.39
Extreme 3.39
9
3 years 3.39
Extreme 3.39
9
5 years 3.39
Extreme 3.39
9
10 years 3.39
Extreme 3.39
19.45
Manager TitleAgeSince
Chief Executive Officer 54 2022-03-21
Director of Finance/CFO 53 2024-07-31
Chief Tech/Sci/R&D Officer - 2025-02-28
Director TitleAgeSince
Chairman 62 2017-06-27
Director/Board Member - 2016-12-31
Director/Board Member 54 2021-11-30
Change 5-day change 1-year change 3-year change Capi.($)
-46.82%0.00% - - 56.9M
-0.49%+0.37%+72.82%+42.43% 138B
+1.25%-2.40%+6.58%+32.04% 82.5B
-1.65%+2.44%+2.29%+50.51% 28.01B
+8.61%+8.83%+33.68%+57.86% 23.23B
+1.32%0.00%-14.98%-28.49% 19.79B
+1.88%-0.09%+25.72%+159.24% 16.83B
+0.94%+0.11%+54.82%+127.93% 14.9B
-2.38%-6.13%+1.72%-2.46% 14.98B
+0.58%+2.24%-6.44%-12.01% 12.96B
Average -3.68%+0.80%+19.58%+47.45% 39.01B
Weighted average by Cap. +0.66%+0.26%+35.11%+42.96%

Financials

2026 *2027 *
Net sales 85M 96.65M 78.96M 72.63M 136M 9.36B 139M 944M 368M 4.57B 363M 355M 15.84B 88.4M 101M 82.12M 75.53M 142M 9.73B 144M 982M 383M 4.75B 377M 369M 16.47B
Net income 300K 341K 279K 256K 481K 33.03M 489K 3.33M 1.3M 16.11M 1.28M 1.25M 55.9M 1M 1.14M 929K 854K 1.6M 110M 1.63M 11.11M 4.33M 53.71M 4.27M 4.18M 186M
Net Debt 8M 9.1M 7.43M 6.84M 12.82M 881M 13.05M 88.87M 34.66M 430M 34.15M 33.41M 1.49B 6M 6.82M 5.57M 5.13M 9.61M 661M 9.79M 66.65M 26M 322M 25.61M 25.06M 1.12B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
723
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.860EUR
Average target price
6.500EUR
Spread / Average Target
+127.27%

Annual profits - Rate of surprise